COLUMBIA, Md., Nov 03, 2009 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), today announced that the company has achieved a $15 million milestone payment from NuVasive (NASDAQ: NUVA) related to the sale of the Osteocel business. Triggering the payment, NuVasive recently reached $35 million in cumulative ...  

COLUMBIA, Md., Sep 30, 2009 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading stem cell therapeutic company focused on developing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas, announced today that C. Randal Mills, Ph.D., President and Chief Execut...  

COLUMBIA, Md., Sep 08, 2009 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced preliminary results for two phase III trials evaluating Prochymal for the treatment of acute graft versus host disease (GvHD). GvHD, the most common complication of bone marrow transplantation, is a life-threatenin...  

COLUMBIA, Md., Aug 04, 2009 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) today announced the creation of a new Biosurgery Division focused on developing and marketing high-end biological products for use in surgical procedures. The company intends to build on the success of its first generation implanta...  

COLUMBIA, Md., Jul 27, 2009 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) today announced that it will report its financial results for the quarter ended June 30, 2009, on Thursday, August 6, 2009. C. Randal Mills, Ph.D., President and Chief Executive Officer, and Richard Hunt, Chief Financial Officer, w...